Gold prices steady ahead of Fed decision; weekly weakness noted
LONDON - PureTech Health plc (Nasdaq:PRTC, LSE: PRTC) has issued ordinary shares to four executives following the vesting of restricted share units (RSUs), according to a company statement released Friday.
The biotherapeutics company issued a total of 291,720 ordinary shares to key personnel after the vesting of one-third of RSUs that were granted on June 26, 2024, under its Performance Share Plan. The shares were distributed after deductions for payroll taxes.
Chief Executive Officer Bharatt Chowrira received 167,739 shares, President Eric Elenko received 56,735 shares, Chief Accounting Officer Michael Inbar received 30,245 shares, and General Counsel Charles Sherwood received 37,001 shares.
The market price used to calculate the amount payable and shares to be issued was 125.80 pence per ordinary share, based on the average closing price over the three trading days before issuance. An exchange rate of £1 to $1.37 was applied for cash payment calculations.
Following this issuance, PureTech’s total issued ordinary share capital stands at 257,927,489 shares, with 16,611,162 shares held in treasury.
The notification was made in accordance with Article 19 of the EU Market Abuse Regulation, as stated in the company’s press release.
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine for patients with various diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.